Navigation Links
Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
Date:5/24/2011

gouty arthritis is estimated to be five times more prevalent than rheumatoid arthritis in the US(5,6).  

"We are very excited about these results, which indicate that ACZ885 may become a significant new alternative for gouty arthritis patients where many standard anti-inflammatory treatments are inadequate or inappropriate," said David Epstein, Head of the Pharmaceuticals Division of Novartis. "Novartis is committed to meeting this unmet medical need and to further investigating the potential of ACZ885 in a number of other conditions where interleukin-1 beta may play a role."

Gouty arthritis attacks occur when the body has a strong inflammatory response to uric acid crystals forming in the affected joint, typically of the toe, foot, ankle or knee(7-9). This intense inflammatory response causes the severe pain and other debilitating symptoms associated with gouty arthritis attacks, which can last for a week or more(3,9-11).

Treatments currently available to manage the pain and inflammation of gouty arthritis attacks, such as NSAIDs or colchicine, may be inadequate or inappropriate in patients who have coexisting medical problems(12-14). This poses a significant unmet treatment need in gouty arthritis. In the US alone, more than 95% of patients with gouty arthritis or high uric acid levels (hyperuricemia) have at least one coexisting disease(15), a portion of whom may be unable to take these standard therapies.

Regulatory filings for the use of ACZ885 in gouty arthritis patients with limited treatment options were submitted in the EU in 2010 and in the US, Canada and Switzerland in the first quarter of 2011. ACZ885 is currently approved in the US and other countries for a different disease state.

About the StudiesThe two studies were Phase III, 12-week, randomized, multicenter, double-blind, double dummy, active-controlled studies involving 228 and 226 patients who met the American College of Rheumatology (ACR) criteria for
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced the ... evaluating aldoxorubicin compared to topotecan in subjects with ... relapsed or were refractory to prior chemotherapy. Aldoxorubicin ... agent, doxorubicin. CytRx has received Orphan Drug Designation ...
(Date:9/29/2014)... et SAN DIEGO , 29 ... (ci-après désignée Daiichi Sankyo) (TSE : 4568) et Ambit ... conclusion d,un accord de fusion définitif en vertu ... des actions ordinaires en circulation d,Ambit Biosciences à ... biais d,une offre publique d,achat qui sera suivie ...
(Date:9/29/2014)... , Sept. 29, 2014  Bob Pack, who lost ... called on the California Medical Association to immediately cease ... that the San Jose Mercury News called "shamelessly deceptive" ... it wants voters to believe about the measure is ... the Prop 46 requirement that doctors check ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 2Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 4Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 5
(Date:9/30/2014)... York, New York (PRWEB) September 30, 2014 ... honor Kenro Izu – founder of the nonprofit, Friends ... on November 6, 2014, for building a hospital in ... pediatric care. , Izu first encountered Cambodia’s appalling ... from a variety of disabilities and illnesses during a ...
(Date:9/30/2014)... OH (PRWEB) September 30, 2014 ... blades sporting the iconic pink ribbon in support of ... a popular month for businesses and non-profits to “go ... worthwhile cause. , AutoTex PINK is a woman-owned company ... wipers. They are committed to partnering with their ...
(Date:9/30/2014)... September 30, 2014 Teeth replacement and ... Art Institute in Oxnard and Thousand Oaks, Calif., is ... tomorrow to provide training on full mouth rehabilitation. , ... placing implants, providing cosmetic dentistry, correcting bite issues, and ... , Dr. Jivraj, who has traveled to India to ...
(Date:9/30/2014)... 30, 2014 Loffler Companies, an ... technology and services was recognized by BEI as ... (FCE) in 2013. This prestigious rating means that ... time and for an extended period following, optimizing ... 20 years BEI Services has been the trusted ...
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 In ... commemorate breast cancer survivors and their courageous battles, Incredible ... to start afresh with PicoSure® by Cynosure. , ... blue or black tattoo is applied on their skin ... explains Dr. Sam Ebrahimi. “For many survivors, they decide ...
Breaking Medicine News(10 mins):Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 2Health News:Nobel Prize For Child Advocates Announces 2014 Health Award Honoree 3Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 2Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 3Health News:Incredible Veins, Body & Skin Takes A Stand Against Breast Cancer With PicoSure® By Cynosure 2
... D.I.S.C. Spine and,Sports Center, proudly announces ... initial 18 months of operation where over ... Robert S. Bray Jr., founding director and,CEO. ... medical group,providing next generation diagnostics, conservative care, ...
... More than 500 hospital and supplier representatives expected ... all supply chain participants, LOUISVILLE, Colo., March ... will gather in Chicago, April 16-18 for the ... and identify opportunities,for greater collaboration to improve operational ...
... time of year when more,than 1.5 million high school and ... and drink large quantities of alcohol. Students who,vacation with friends ... who stay home with parents or relatives, according to a ... on Alcohol and Drugs., Instead of just telling students ...
... to help caregivers,maintain a sense of balance in their ... the focus of a recently published free Caregiver,s,guide. Today, ... and the free caregivers, guide will help them enhance ... guide provides caregivers with an easy-to-implement and inexpensive,way to ...
... Mich., March 25 Plexus Systems, Inc. ... about efficient manufacturing,operations on Thursday, March 27 ... entitled Smart Manufacturing! Manufacturing IQ & Manufacturing,Operations ... and best practices to achieve quality and ...
... family history are referred less often than whites, study finds ... is a family history of colon cancer, blacks are much ... a new study finds. , While blacks who have an ... their white counterparts in colonoscopy rates, the lack of a ...
Cached Medicine News:Health News:Zero Patient Infections Reported as D.I.S.C. Spine and Sports Center Sets New Standard for Specialty Hospitals 2Health News:The Healthcare Supply Chain to Connect in Chicago for the 2008 GHX Supply Chain Summit 2Health News:It's Spring Break: How Much Does Heavy Drinking Affect Your Body? 2Health News:Free Caregiver's Guide Helps Caregivers & Loved-Ones 2Health News:Plexus Systems, Inc. and Aberdeen Group Co-host March 27 Webinar on Manufacturing Efficiency 2Health News:Plexus Systems, Inc. and Aberdeen Group Co-host March 27 Webinar on Manufacturing Efficiency 3Health News:High-Risk Blacks Less Likely to Get Colonoscopies 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: